Yes, it is—100%.
There is a desire to push this through now to regulations. What we'll also see is a push to regulate the use of these platforms for other drugs, because once you have a [Technical difficulty—Editor] for one, then it's easier to enter any other type of indication.
I definitely think that we need to wait and understand how these work—at a minimum the biodistribution and expression data, for sure.